ArticleJournal of thoracic disease2018
Risk factors for primary Sjögren syndrome-associated interstitial lung disease.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Sjögren's Syndrome and Ankylosing Spondylitis Association: A Case-Based Review.Current rheumatology reviews · 2025Pooled it
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis care & research · 2024Guideline
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.Arthritis & rheumatology (Hoboken, N.J.) · 2024Guideline
- Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.BMJ open respiratory research · 2023Pooled it
- Biomarkers of interstitial lung disease associated with primary Sjögren's syndrome.European journal of medical research · 2022Trial
- Evaluation of patients diagnosed with primary Sjogren's syndrome with and without pulmonary involvement.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Clinical, radiologic, and serologic predictors of rheumatic disease in interstitial lung disease patients.Clinical rheumatology · 2025Article
- The Role of Anti-SSB/La Antibodies as Predictors of Decreased Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) in Primary Sjögren Disease.International journal of molecular sciences · 2025Article
- Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome: A Systematic Review and Meta-analysis of Observational Studies : Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome.Galen medical journal · 2025Review
- Interstitial Lung Disease in Primary Sjögren's Syndrome: Risk factors for occurrence and radiographic progression.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Long-term functional course of Sjögren's disease-associated interstitial lung disease.ERJ open research · 2024Article
- Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome.Journal of clinical medicine · 2024Article
- Interstitial lung disease and associated factors in patients with Sjögren's syndrome.Irish journal of medical science · 2024Article
- Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review.Revista colombiana de reumatologia · 2024Article
- Clinical Characteristics and Outcomes of Interstitial Lung Disease in Primary Sjögren's Syndrome: A Retrospective Cohort Study.Mediterranean journal of rheumatology · 2024Article
- Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.Clinical rheumatology · 2024Article
- The analysis of the pulmonary domain involvement in Sjögren's disease.Therapeutic advances in musculoskeletal disease · 2024Article
- Risk factors for cardiovascular disease in primary Sjögren's syndrome (pSS): a 20-year follow-up study.Clinical rheumatology · 2023Article
- Tobacco smoking is associated with combined pulmonary fibrosis and emphysema and worse outcomes in interstitial lung disease.American journal of physiology. Lung cellular and molecular physiology · 2023Article
- The characteristics of chest HRCT and pulmonary function tests in lung-onset primary sjogren's syndrome.Immunity, inflammation and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary Sjögren syndrome (pSS) is a chronic inflammatory autoimmune disease that is characterized by lymphocytic infiltration of the exocrine glands and extraglandular organ systems. Interstitial lung disease (ILD) is common in pSS patients and is one of the independent risk factors for a poor prognosis. The previously reported characteristics and potential risks contributing to pSS-associated ILD have been controversial.
methodsA cohort of 201 newly diagnosed pSS patients were studied over a period of 3 years. Data were from clinical charts. The pSS patients were classified into two groups, namely pSS-ILD or pSS without ILD, according to the lung evaluation.
resultsIn total, the prevalence of pSS-associated ILD was 78.6%. The pSS patients associated ILD were more likely to be male, older and smokers in comparison to the pSS patients without ILD. There were no significant differences in multiorgan involvement between the two groups. Nonspecific interstitial pneumonia (NSIP) was the most common radiological pattern (45.5%). pSS with ILD was associated with increasing age [odds ratio (OR) =1.073], smoking (OR =8.544) and antinuclear antibody (ANA) positive (OR =3.286). Over a median follow-up period of 24 months (range, 18-30 months), no patients died, experienced acute exacerbation of ILD, or had newly diagnosed pSS-ILD.
conclusionspSS associated ILD were more commonly in males, older patients and smokers. Aging, cigarette smoking, and ANA positivity may be potential risk factors contributing to ILD in pSS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.